Oncolytics Biotech Inc. December 2024 Financial Report Insights

Here are the key insights extracted from the financial report based on the provided document:

1. Form Type and Purpose: The document is a Form 6-K, which is a report filed by foreign private issuers to disclose important information that may be of interest to investors.
2. Company Information:

• Registrant Name: Oncolytics Biotech Inc.
• Commission File Number: 001-38512
• Address: Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.

3. Reporting Period: The report is for the month of December 2024.
4. Filing Status:

• The registrant indicates it will file annual reports under Form 20-F.
• It is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or 101(b)(7).

5. Signatory Authority:

• The report is signed by Kirk Look, who is identified as the Chief Financial Officer, confirming the authenticity and approval of the report.

6. Date of Signing: December 18, 2024.
7. Exhibits: The document references an exhibit (99.1) which is a press release, suggesting that additional information or context is provided in an attached or linked document.

This summary encapsulates the essential elements of the report, focusing on compliance, company identification, and governance structure.